1338 studies found for:    Open Studies | "Lymphoma"
Show Display Options
Rank Status Study
21 Not yet recruiting Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: lomustine;   Drug: etoposide;   Drug: procarbazine hydrochloride;   Other: laboratory biomarker analysis
22 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: Adcetris;   Drug: Bendamustine
23 Recruiting PI3K Inhibitor BKM120 in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: PI3K inhibitor BKM120;   Other: laboratory biomarker analysis
24 Recruiting TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Biological: ipilimumab;   Drug: TLR9 agonist SD-101;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
25 Recruiting CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Conditions: ALK-negative Anaplastic Large Cell Lymphoma;   Peripherial T Cell Lymphoma,Not Otherwise Specified;   Angioimmunoblastic T Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Hepatosplenic T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma
Interventions: Drug: Cyclophosphamide 750mg/m2;   Drug: Vincristine 1.4mg/m2;   Drug: Doxorubicin 50mg/m2;   Drug: prednisone 60mg/m2;   Drug: ifosfamide 2000mg/m2;   Drug: pirarubicin 50mg/m2;   Drug: pirarubicin 25mg/m2;   Drug: Etoposide phosphate 100mg/m2;   Drug: methotrexate 1500mg/m2
26 Recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   HIV Infection
Interventions: Drug: busulfan;   Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Other: pharmacological study;   Other: laboratory biomarker analysis
27 Recruiting A Safety Study of SGN-CD19A for B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Lymphoma, Follicular;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Mantle-Cell;   Precursor B-cell Lymphoblastic Leukemia-Lymphoma
Intervention: Drug: SGN-CD19A
28 Recruiting Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Conditions: CD20+, B-cell Lymphomas;   Mantle Cell Lymphoma;   Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL);   Transformed Lymphoma/DLBCL/PMBCL;   Hodgkin's Disease
Intervention: Drug: Everolimus and Rituximab
29 Recruiting Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Burkitt Lymphoma;   Diffuse Large Cell Lymphoma;   'Grey Zone' Lymphoma;   Lymphoblastic Lymphoma;   Anaplastic Large Cell Lymphoma;   Hodgkin Lymphoma
Intervention: Drug: CPX-351
30 Recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
31 Recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma;   Lymphoma, Primary Cutaneous Anaplastic Large Cell;   Lymphomatoid Papulosis;   Mycosis Fungoides;   Skin Lymphoma;   Cutaneous Lymphomas;   Lymphoma;   Hematologic Disorder
Intervention: Drug: SGN-35
32 Recruiting A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: rituximab
33 Recruiting Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib;   Biological: rituximab;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: DNA analysis;   Other: pharmacological study;   Other: pharmacogenomic studies
34 Recruiting Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: ofatumumab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography with radiolabeled targeting agents;   Radiation: fludeoxyglucose F 18
35 Unknown  Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Conditions: Peripheral T Cell Lymphoma, Unspecified;   Angioimmunoblastic Lymphadenopathy;   Extranodal NK/T-cell Lymphoma
Interventions: Biological: alemtuzumab;   Drug: chemotherapy
36 Recruiting Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: belinostat;   Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
37 Recruiting Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Conditions: Peripheral T-cell Lymphomas (PTCL);   Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS),;   Angioimmunoblastic T-cell Lymphoma (AITL);   ALK- Anaplastic Largecell Lymphoma (ALCL).
Interventions: Drug: Ro-CHOEP-21 (PHASE I);   Drug: Ro-CHOEP-21 (PHASE II)
38 Not yet recruiting Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Conditions: Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: ibrutinib;   Other: laboratory biomarker analysis
39 Recruiting EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Conditions: Lymphoma, AIDS-related;   Lymphoma, Large B-cell, Diffuse
Interventions: Biological: Rituximab;   Biological: filgrastim;   Drug: EPOCH
40 Recruiting Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
Conditions: Peripheral T-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma
Interventions: Drug: oral JAK inhibitor INCB18424;   Other: laboratory biomarker analysis;   Other: pharmacological study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years